LSD1 Antibody

Western Blot: LSD1 Antibody [NBP3-18684]

Western Blot: LSD1 Antibody [NBP3-18684] - Figure 5. Western blot analysis using the antibody directed against LSD1 Whole cell extracts (40 ug) from HeLa cells transfected with LSD1 siRNA (lane 2) and from an untransfected control (lane 1) were analysed by Western blot using the antibody against LSD1 diluted 1:5,000 in TBS-Tween containing 5% skimmed milk. The position of the protein of interest is indicated on the right; the marker (in kDa) is shown on the left.

Immunocytochemistry/ Immunofluorescence: LSD1 Antibody [NBP3-18684]

Immunocytochemistry/Immunofluorescence: LSD1 Antibody [NBP3-18684] - Figure 6. Immunofluorescence using the antibody directed against LSD1 HeLa cells were stained with the antibody against LSD1 and with DAPI. Cells were fixed with 4% formaldehyde for 10 and blocked with PBS/TX-100 containing 5% normal goat serum and 1% BSA. The cells were immunofluorescently labelled with the LSD1 antibody (left) diluted 1:200 in blocking solution followed by an anti-rabbit antibody conjugated to Alexa488. The middle panel shows staining of the nuclei with DAPI. A merge of the two stainings is shown on the right.

Chromatin Immunoprecipitation Sequencing: LSD1 Antibody [NBP3-18684] - Figure 2. ChIP-seq results obtained with the antibody directed against LSD1 ChIP was performed on sheared chromatin from 4,000,000 K562 cells using 1 ug of the antibody against LSD1 as described above. The IPd DNA was subsequently analysed on an Illumina HiSeq. Library preparation, cluster generation and sequencing were performed according to the manufacturers instructions. The 50 bp tags were aligned to the human genome using the BWA algorithm. Figure 2 shows the peak distribution along the complete sequence and a 600 kb region of the X-chromosome (figure 2A and B) and in three regions surrounding the MYT1, RBM19 and TGFBR3 positive control genes, respectively (figure 2C, D and E). The position of the amplicon used for ChIP-qPCR is indicated by an arrow.